Signaturefd LLC acquired a new position in Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 3,295 shares of the company’s stock, valued at approximately $277,000.

Other hedge funds also recently added to or reduced their stakes in the company. Parametrica Management Ltd bought a new stake in Eli Lilly and during the first quarter worth $242,000. First Command Financial Services Inc. boosted its stake in Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock worth $103,000 after buying an additional 84 shares during the last quarter. Prospera Financial Services Inc boosted its stake in Eli Lilly and by 6.7% in the first quarter. Prospera Financial Services Inc now owns 14,258 shares of the company’s stock worth $1,208,000 after buying an additional 895 shares during the last quarter. Alpha Windward LLC boosted its stake in Eli Lilly and by 2.0% in the first quarter. Alpha Windward LLC now owns 2,251 shares of the company’s stock worth $189,000 after buying an additional 44 shares during the last quarter. Finally, Private Trust Co. NA boosted its stake in Eli Lilly and by 43.5% in the first quarter. Private Trust Co. NA now owns 7,787 shares of the company’s stock worth $654,000 after buying an additional 2,360 shares during the last quarter. 75.61% of the stock is currently owned by institutional investors.

Eli Lilly and Company (LLY) traded down 0.47% during trading on Friday, reaching $81.15. 2,446,392 shares of the company were exchanged. The firm’s 50 day moving average is $82.91 and its 200 day moving average is $81.72. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The stock has a market capitalization of $85.61 billion, a PE ratio of 35.11 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.05 by $0.06. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. During the same quarter last year, the company posted $0.86 EPS. Eli Lilly and’s revenue for the quarter was up 7.8% on a year-over-year basis. Analysts expect that Eli Lilly and Company will post $4.16 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be given a $0.52 dividend. The ex-dividend date is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.56%. Eli Lilly and’s dividend payout ratio (DPR) is 90.04%.

TRADEMARK VIOLATION WARNING: “Signaturefd LLC Acquires Shares of 3,295 Eli Lilly and Company (NYSE:LLY)” was first reported by Daily Political and is the property of of Daily Political. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.dailypolitical.com/2017/08/12/signaturefd-llc-acquires-shares-of-3295-eli-lilly-and-company-nyselly.html.

A number of research firms have weighed in on LLY. Cowen and Company raised their price objective on shares of Eli Lilly and from $85.00 to $95.00 and gave the stock an “outperform” rating in a report on Monday, April 17th. Morgan Stanley cut shares of Eli Lilly and from an “overweight” rating to an “equal weight” rating and set a $82.00 price objective on the stock. in a report on Monday, April 17th. Piper Jaffray Companies reissued a “buy” rating and set a $100.00 price objective on shares of Eli Lilly and in a report on Monday, April 17th. BMO Capital Markets cut shares of Eli Lilly and from a “market perform” rating to an “underperform” rating and cut their price objective for the stock from $73.00 to $71.00 in a report on Monday, April 17th. Finally, Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective on the stock in a report on Monday, July 17th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $88.27.

In related news, major shareholder Lilly Endowment Inc sold 220,000 shares of the stock in a transaction on Monday, July 31st. The stock was sold at an average price of $83.09, for a total value of $18,279,800.00. Following the completion of the transaction, the insider now owns 124,049,283 shares in the company, valued at approximately $10,307,254,924.47. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Michael J. Harrington sold 22,833 shares of the stock in a transaction on Friday, June 9th. The shares were sold at an average price of $79.97, for a total value of $1,825,955.01. Following the completion of the transaction, the vice president now owns 62,056 shares of the company’s stock, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. Insiders sold a total of 669,733 shares of company stock valued at $55,845,287 in the last quarter. 0.20% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.